The Lynx Group

Genitourinary Cancers

The addition of sacituzumab govitecan (Trodelvy), an antibody–drug conjugate, to the PD-1 inhibitor pembrolizumab (Keytruda) showed encouraging antitumor activity in checkpoint inhibitor–naïve patients with metastatic urothelial cancer, according to an analysis of the results of cohort 3 from the phase 2 TROPHY-U-01 clinical trial.
Read Article

Combining the PARP inhibitor olaparib (Lynparza) with abir­aterone acetate (Zytiga) led to a statistically significant and clinically meaningful improvement in radiographic progression-free survival (PFS) versus abiraterone alone in patients with metastatic castration-resistant prostate cancer (mCRPC), regardless of homologous recombination repair (HRR) status, according to results of the phase 3 PROpel trial.
Read Article

San Francisco, CA—De-escalating chemotherapy based on a negative positron- emission tomography (PET) scan after 2 cycles of treatment is safe and feasible in most patients with low-volume metastatic seminoma, the most common type of testicular cancer, according to results presented at the 2020 Genitourinary Cancers Symposium.
Read Article

San Francisco, CA—Delivering the keynote address at the 2020 Genitourinary Cancers Symposium, David F. Penson, MD, MPH, MMHC, Hamilton and Howd Chair in Urologic Oncology, Vanderbilt University Medical Center, Nashville, TN, highlighted the need to move toward patient-centered decisions beyond survival, focusing on patient-centered outcomes by integrating quality of life (QOL) and financial toxicity into the shared, treatment-related, decision- making process.

Read Article

San Francisco, CA—MicroRNAs have all the characteristics to be a potential game changer as a biomarker in germcell tumors (originating in the testes, ovaries, and a few other sites), with high sensitivity, specificity, and clinical validity in pilot studies, said Lucia Nappi, MD, PhD, Medical Oncologist, British Columbia Cancer, Vancouver Centre, Canada, at the 2020 Genitourinary Cancers Symposium.

Read Article

Orlando, FL—The incidence of bladder cancer is on the rise, and bladder cancer is 4 to 5 times more expensive to treat than breast or prostate cancer. The cost of bladder cancer treatment can be reduced by adhering to the National Comprehensive Cancer Network or the American Urological Association treatment guidelines.
Read Article

Orlando, FL—Clinical trials involving immunotherapy have increased in the past few years, and the oncology community is eagerly awaiting the results. However, not so well-known is what happens to patients who receive immunotherapy outside of the clinical trial setting, including those who are not eligible for clinical trials.
Read Article

Orlando, FL—One cycle of the bleomycin, etoposide, and cisplatin (BEP) regimen had less toxicity and was as effective as 2 cycles in patients with high-risk, nonseminomatous or germ-cell tumors of the testis (NSGCTT), according to results of a large prospective trial called 111 presented at the 2017 Genitourinary Cancers Symposium. Using 1 cycle of BEP as standard of care would reduce exposure to toxicity, and most patients with testicular cancer are relatively young.
Read Article

In the United States, the standard of care for locally advanced bladder cancer after radical cystectomy is to “consider” adjuvant chemotherapy and ad­juvant radiation. Results of a 3-arm randomized clinical trial showed that adjuvant radiation therapy alone or combined with chemotherapy (ie, chemoradiotherapy) did not significantly improve disease-free survival compared with adjuvant chemotherapy alone. However, the findings hint at benefits for chemoradiotherapy that should be studied further. Brian Baumann, MD, a radiation oncology resident at the University of Pennsylvania, Philadelphia, presented the findings at the 2016 Genitourinary Cancers Symposium.
Read Article

High-risk patients with metastatic renal-cell carcinoma (RCC) and venous tumor thrombus derived no benefit from cytoreductive nephrectomy and should be evaluated for clinical trials of systemic therapy, suggested a retrospective multicenter review.
Read Article

Page 1 of 2


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: